Challenges in Treating Pediatric Cancer Patients during the COVID-19 Pandemic: Balancing Risks and Care

Area of Science:

• Oncology
• Infectious Diseases
• Pediatrics

Background:

• The COVID-19 pandemic poses significant risks to pediatric cancer patients, a vulnerable population.
• Limited research exists on symptom detection and disease mechanism modification in this cohort.
• Understanding virus-treatment interactions is crucial for managing COVID-19 in pediatric oncology.

Purpose of the Study:

• To review and expose treatment challenges for pediatric cancer patients with COVID-19.
• To synthesize existing studies on managing COVID-19 in pediatric oncology.
• To include updated information on antiviral agents like Remdesivir and Paxlovid in this patient group.

Main Methods:

• Systematic review and synthesis of existing scientific literature.
• Inclusion of studies focusing on pediatric cancer patients with COVID-19.
• Analysis of data concerning treatment strategies and antiviral use.

Main Results:

• No specific COVID-19 treatment exists exclusively for pediatric cancer patients.
• Antiviral agents Remdesivir and Paxlovid have been studied in this population.
• Self-medication should be avoided due to potential side effects.
• New strategies like specialized chemotherapy rooms are implemented for asymptomatic pediatric cancer patients with COVID-19.

Conclusions:

• Managing COVID-19 in pediatric cancer patients is a substantial challenge.
• The risk of disease progression in cancer outweighs the risk of SARS-CoV-2 complications for asymptomatic cases.
• Further research is needed to establish optimal treatment protocols.